Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05192109 · ClinicalTrials.gov registry record · NA

Study 2: Learning New Words From Overhearing in Children With Autism Spectrum Disorder (ASD)

A NA study, sponsored by New York University.

Completed
Registry status
NA
Development phase
342
Enrollment target

NCT05192109: Completed NA study, sponsored by New York University.

NCT05192109 is a NA study that has completed, run by New York University. The registered enrollment target is 342 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05192109, a NA study, has completed, sponsored by New York University.

COMPLETED
Registry status
NA
Development phase
342 participants
Enrollment target

Study Summary

The goal of this research is to explore abilities to learn word meanings from overheard conversations in children with ASD (and, as a control, typically developing children). Specific Aim 2 (Experiment 2): Determine whether children with ASD can learn from addressed and overheard teaching via videoconferencing. The investigators will use a similar procedure to Study 1, except that both overheard and directed teaching will take place on video.

Primary Outcome

Children's eye gaze is recorded as they look at images. The proportion of time during which gaze is directed to an image of the targeted word is the dependent measure.

Interventions

  • BEHAVIORAL Overheard Speech
  • BEHAVIORAL Addressed Speech

Trial Details

FieldValue
Enrollment Target 342 participants
Start Date 2020-12-01
Est. Completion 2024-12-05
Phase NA
New York University

83 total trials

What the finished NCT05192109 record still lists

NCT05192109 is an interventional study that assigns participants to a tested intervention. The registered 342 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower).

The record links to 0 conditions, and to 2 interventions - of which Overheard Speech is the first listed.

NCT05192109 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05192109 about?

NCT05192109 is a clinical study titled "Study 2: Learning New Words From Overhearing in Children With Autism Spectrum Disorder (ASD)". The goal of this research is to explore abilities to learn word meanings from overheard conversations in children with ASD (and, as a control, typically developing children). Specific Aim 2 (Experiment 2): Determine whether children with ASD can learn from addressed and overheard teaching via video...

What is the current status of trial NCT05192109?

This trial is currently completed. It is a NA study. The enrollment target is 342 participants. The study started on 2020-12-01. Estimated completion is 2024-12-05.

What interventions are being tested in trial NCT05192109?

The interventions under investigation include: Overheard Speech (BEHAVIORAL), Addressed Speech (BEHAVIORAL).

Who is sponsoring clinical trial NCT05192109?

This trial is sponsored by New York University, which has 83 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05192109's enrollment target sits among peer trials

342 302nd of 2000 higher than 1,699 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05283850 · 342 participants · Phase 2

    Surviving PEA in Roanoke (SPEAR) Study

  • NCT05714085 · 342 participants · Phase 2

    Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

  • NCT06188702 · 342 participants · Phase 1

    S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

  • NCT06544941 · 342 participants · NA

    Improving Maternal Sleep and Mental Health

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05192109, the US trial registry maintained by the National Library of Medicine. NCT05192109 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.